文献速递性腺与生殖内分泌糖尿病

内源性睾酮、睾酮治疗与男性心血管健康结局

Endogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文为叙述性综述,总结观察性与干预性研究中睾酮与心血管健康结局的关系。观察性研究显示低内源性睾酮与全因死亡率相关,但非心血管事件;T4DM 试验中睾酮治疗降低糖代谢异常男性 2 型糖尿病风险,TRAVERSE 试验未发现主要心血管不良事件风险增加。

要点

  • 低内源性睾酮与全因死亡率升高相关,但未证实与心血管事件或心血管死亡相关。
  • T4DM 试验中睾酮治疗在生活方式干预基础上降低糖代谢异常男性 2 年 2 型糖尿病风险。
  • TRAVERSE 试验中睾酮治疗未增加心血管疾病或多种危险因素男性的主要心血管不良事件风险。

核心结论

  • 低内源性睾酮与全因死亡率升高相关,但观察性研究未一致证实其与心血管事件或心血管死亡相关。
  • 睾酮治疗在糖代谢异常男性中可降低 2 型糖尿病风险,在心血管疾病或多种危险因素男性中未增加主要心血管不良事件风险。

研究设计与样本

  • 叙述性综述,汇总观察性研究与干预性研究,包括英国生物银行前瞻性队列、个体参与者数据荟萃分析、T4DM 随机安慰剂对照试验和 TRAVERSE 心血管安全性试验。

主要发现

  • 横断面分析显示低内源性睾酮见于已有心血管疾病的男性,但年龄>70 岁、较高体重指数及糖尿病或癌症等合并症影响更大。
  • 英国生物银行中低内源性睾酮与全因死亡率升高相关,但与 incident 心血管事件或心血管死亡无关。
  • 个体参与者数据荟萃分析显示基线睾酮与全因死亡率和心血管死亡率呈非线性关联,风险分别在睾酮<7.4 nmol/L(213 ng/dL)和<5.3 nmol/L(153 ng/dL)时升高。
  • T4DM 试验中睾酮治疗在生活方式干预基础上降低糖代谢异常男性 2 年后 2 型糖尿病风险。
  • TRAVERSE 试验中睾酮治疗组与安慰剂组相比主要心血管不良事件风险未增加,平均随访 3 年。

关键数值与推荐

  • 个体参与者数据荟萃分析中,全因死亡率风险在基线睾酮<7.4 nmol/L(213 ng/dL)时升高。
  • 个体参与者数据荟萃分析中,心血管死亡率风险在基线睾酮<5.3 nmol/L(153 ng/dL)时升高。

临床怎么用

  • 评估男性低睾酮时需考虑年龄>70 岁、较高体重指数及糖尿病或癌症等合并症对心血管风险的影响。
  • 对糖代谢异常男性,睾酮治疗联合生活方式干预可能降低 2 型糖尿病风险。
  • 对有心血管疾病或多种危险因素的男性,睾酮治疗未增加主要心血管不良事件风险,但长期安全性需进一步研究。

局限性

  • 需额外研究确认长期心血管安全性,并探索体成分和心脏代谢风险变化相关的可能心血管获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whether lower testosterone concentrations in aging men predispose to poorer health, particularly cardiovascular disease (CVD), remains controversial. This narrative review summarizes the relationships between testosterone and cardiovascular health outcomes, based on observational and interventional studies. Cross-sectional analyses show that lower endogenous testosterone concentrations are found in men with preexisting CVD, but larger influences are age > 70 years, higher body mass index, and medical comorbidities such as diabetes or cancer. In the United Kingdom Biobank, the largest prospective cohort study to date, lower endogenous testosterone concentrations were associated with higher risk of all-cause mortality, but not incident cardiovascular events or CVD deaths. In an individual participant data meta-analysis of prospective cohort studies with testosterone measured using mass spectrometry, there were nonlinear associations of baseline testosterone concentrations with higher all-cause and cardiovascular mortality, with these risks increasing below thresholds of testosterone < 7.4 nmol/L (213 ng/dL) and < 5.3 nmol/L (153 ng/dL), respectively. In the randomized, placebo-controlled T4DM trial involving men with dysglycemia, testosterone treatment on a background of lifestyle intervention reduced risk of type 2 diabetes mellitus after 2 years. The TRAVERSE cardiovascular safety trial, conducted in men with CVD or multiple risk factors, found no increased risk of major adverse cardiovascular events in men randomized to testosterone treatment vs placebo, with average follow-up of 3 years. Based on epidemiological studies, and the results of T4DM and TRAVERSE, additional studies are needed to confirm long-term cardiovascular safety, and explore possible cardiovascular benefits related to changes in body composition and cardiometabolic risk.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yeap BB, Anawalt BD. Endogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men. J Clin Endocrinol Metab. 2026. PMID: 41223023. doi:10.1210/clinem/dgaf622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。